-
JBCRG-C02
Observational study to evaluate the usefulness of trastuzumab in recurrent breast cancer patients with prior adjuvant chemotherapy with trastuzumab: Cohort II
- Status
-
Study Closed
- Objectives
-
To evaluate the efficacy and safety of trastuzumab in patients with recurrent breast cancer who previously received adjuvant therapy with trastuzumab in clinical settings in Japan
- Subjects
-
- Endpoints
-
Primary endpoint：Progression-free Survival, Secondary endpoint: Histologic effect, Overall survival, Safety
- Trial Period
-
July 2009 - June 2014
- Lead Principal Investigator
-
Hiroyasu Yamashiro(Dept of Breast Surgry, Kyoto University Hospital)
- Target Sample Size
-
100
- Regimen
-
- Source of Funding
-
- Conference Presentation
-
- Articles and Publications
-
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
- UMIN-ID
-
UMIN000002738
- jRCT
-
- Memo
-
- COI Disclosure
-
